The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 ...

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...